April 27, 2023 | Ophthalmology Times

ARVO LIVE: Ascidian Therapeutics’ research into gene therapy

March 16, 2023 | Cell & Gene Podcast

The Potential Of RNA Exon Editing With Ascidian Therapeutics’ Romesh Subramanian, Ph.D.

March 6, 2023 | Nature Biotechnology

Shoot the messenger: RNA editing is here

February 14, 2023 | Drug Discovery News

Gene editing: DNA versus RNA

December 15, 2022 | PM360

PM360 2022 Innovative Startup: Ascidian Therapeutics

October 13, 2022 | The Boston Globe

Boston startup Ascidian Therapeutics charts vision for therapies that “rewrite RNA”

October 12, 2022 | MedCity News

Sea creature-inspired biotech Ascidian surfaces with $50M and a new way to edit RNA

October 12, 2022 | labiotech.eu

Ascidian Therapeutics launches with $50M to rewrite RNA

October 12, 2022 | GENETIC ENGINEERING & BIOTECHNOLOGY NEWS

Ascidian Therapeutics Launches With RNA Exon Editing Platform

October 12, 2022 | Fierce BioTech

Ascidian Therapeutics rises from ATP’s ocean floor with $50M and Dyne’s former CEO

October 12, 2022 | EndPoints News

Michael Ehlers and Romesh Subramanian launch biotech with $50M, sea squirt-inspired RNA-editing tech

October 12, 2022 | BOSTON BUSINESS JOURNAL

Dyne founder heads up new RNA-editing startup

October 12, 2022 | BIOWORLD

Ascidian closes $50M financing to rewrite the rules of RNA splicing

October 12, 2022 | BIOSPACE

Ascidian Nets $50M to Rewrite RNA in Stargardt Disease and Beyond

October 12, 2022 | BIOPHARMA DIVE

Ascidian starts up with $50M and a twist on RNA editing

October 12, 2022 | BIOCENTURY

Ascidian: correcting mutations via trans-splicing to edit RNA exons